Global Antibiotic R&D Partnership (GARDP)
@gardp.bsky.social
Putting public health needs at the centre of antibiotic drug development to address the crisis of antimicrobial resistance (AMR).
https://gardp.org/this-is-big/
https://gardp.org/this-is-big/
Pinned
🌍🏆 Dr Manica Balasegaram has been named one of TIME’s 100 most influential people in health for advancing and expanding access to new antibiotic treatments so as to tackle antimicrobial resistance.
🔗 Read the TIME feature: time.com/collections/...
#TIME100
🔗 Read the TIME feature: time.com/collections/...
#TIME100
🌍🏆 Dr Manica Balasegaram has been named one of TIME’s 100 most influential people in health for advancing and expanding access to new antibiotic treatments so as to tackle antimicrobial resistance.
🔗 Read the TIME feature: time.com/collections/...
#TIME100
🔗 Read the TIME feature: time.com/collections/...
#TIME100
February 12, 2026 at 11:06 AM
🌍🏆 Dr Manica Balasegaram has been named one of TIME’s 100 most influential people in health for advancing and expanding access to new antibiotic treatments so as to tackle antimicrobial resistance.
🔗 Read the TIME feature: time.com/collections/...
#TIME100
🔗 Read the TIME feature: time.com/collections/...
#TIME100
👩 On the International Day of Women and Girls in Science, Astrid Pentz-Murr reflects on how women’s scientific leadership strengthens antibiotic R&D and drives real public health impact.
At GARDP, supporting women in science is central to advancing better solutions to #AMR.
@astridpm.bsky.social
At GARDP, supporting women in science is central to advancing better solutions to #AMR.
@astridpm.bsky.social
February 11, 2026 at 7:01 AM
👩 On the International Day of Women and Girls in Science, Astrid Pentz-Murr reflects on how women’s scientific leadership strengthens antibiotic R&D and drives real public health impact.
At GARDP, supporting women in science is central to advancing better solutions to #AMR.
@astridpm.bsky.social
At GARDP, supporting women in science is central to advancing better solutions to #AMR.
@astridpm.bsky.social
📢 Hiring
GARDP is looking for a senior medical leader to develop and lead its Medical Sciences function and to shape and deliver medical science strategy across an assigned disease area and portfolio.
📍 Switzerland, UK or Spain (non-US)
🔗 Apply: https://gardp.pulse.ly/63tnadztca
#Careers
GARDP is looking for a senior medical leader to develop and lead its Medical Sciences function and to shape and deliver medical science strategy across an assigned disease area and portfolio.
📍 Switzerland, UK or Spain (non-US)
🔗 Apply: https://gardp.pulse.ly/63tnadztca
#Careers
February 8, 2026 at 6:59 AM
📢 Hiring
GARDP is looking for a senior medical leader to develop and lead its Medical Sciences function and to shape and deliver medical science strategy across an assigned disease area and portfolio.
📍 Switzerland, UK or Spain (non-US)
🔗 Apply: https://gardp.pulse.ly/63tnadztca
#Careers
GARDP is looking for a senior medical leader to develop and lead its Medical Sciences function and to shape and deliver medical science strategy across an assigned disease area and portfolio.
📍 Switzerland, UK or Spain (non-US)
🔗 Apply: https://gardp.pulse.ly/63tnadztca
#Careers
🧬A new #REVIVE viewpoint explores the ongoing challenges in treating carbapenem-resistant Acinetobacter baumannii, outlining where therapies fall short and what’s needed next to improve patient outcomes.
🔗 Read more: revive.gardp.org/managing-aci...
🔗 Read more: revive.gardp.org/managing-aci...
February 6, 2026 at 10:23 AM
🧬A new #REVIVE viewpoint explores the ongoing challenges in treating carbapenem-resistant Acinetobacter baumannii, outlining where therapies fall short and what’s needed next to improve patient outcomes.
🔗 Read more: revive.gardp.org/managing-aci...
🔗 Read more: revive.gardp.org/managing-aci...
🌍📄 GARDP welcomes the development of a new Global Action Plan on AMR that places research, development and access at the core of its objectives.
On behalf of GARDP, Philip Kenol of @dndi.org delivered our statement at the @who.int Executive Board, 158th session.
Watch the clip🔽
On behalf of GARDP, Philip Kenol of @dndi.org delivered our statement at the @who.int Executive Board, 158th session.
Watch the clip🔽
February 5, 2026 at 2:53 PM
🎉🧬 That’s a wrap on #ACC2026
An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next.
Thank you all for the energy and ideas.
See you next year!
🔗Register to watch the recorded sessions and more: acc-conference.com#registration
An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next.
Thank you all for the energy and ideas.
See you next year!
🔗Register to watch the recorded sessions and more: acc-conference.com#registration
February 5, 2026 at 12:28 PM
🎉🧬 That’s a wrap on #ACC2026
An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next.
Thank you all for the energy and ideas.
See you next year!
🔗Register to watch the recorded sessions and more: acc-conference.com#registration
An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next.
Thank you all for the energy and ideas.
See you next year!
🔗Register to watch the recorded sessions and more: acc-conference.com#registration
🔴🚨 FINAL SESSION IS LIVE at #ACC2026
Title: Access isn’t the end, it’s the beginning.
Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access.
🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...
Title: Access isn’t the end, it’s the beginning.
Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access.
🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...
February 5, 2026 at 11:12 AM
🔴🚨 FINAL SESSION IS LIVE at #ACC2026
Title: Access isn’t the end, it’s the beginning.
Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access.
🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...
Title: Access isn’t the end, it’s the beginning.
Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access.
🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...
🔴🚨 Happening LIVE right now
From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children.
🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten...
#ACC2026
From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children.
🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten...
#ACC2026
February 5, 2026 at 9:57 AM
🔴🚨 Happening LIVE right now
From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children.
🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten...
#ACC2026
From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children.
🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten...
#ACC2026
🪧Now live | Session Six at #ACC2026
This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research.
👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...
This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research.
👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...
February 5, 2026 at 9:17 AM
🪧Now live | Session Six at #ACC2026
This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research.
👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...
This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research.
👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...
🚀🔬Day 2 kicks off with Session Five at #ACC2026
Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice.
🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAtten...
@gsk.bsky.social
#AMR #ClinicalDevelopment
Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice.
🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAtten...
@gsk.bsky.social
#AMR #ClinicalDevelopment
February 5, 2026 at 8:11 AM
🚀🔬Day 2 kicks off with Session Five at #ACC2026
Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice.
🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAtten...
@gsk.bsky.social
#AMR #ClinicalDevelopment
Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice.
🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAtten...
@gsk.bsky.social
#AMR #ClinicalDevelopment
🏁✨Final day of #ACC2026
Starting off with Introductory remarks from Dr François Franceschi of GARDP.
One last round of sessions, discussions and shared learning as the conference draws to a close.
✊Let’s finish strong!
🔴🔗Join us live here: portalapp.bsac.eventsair.com/VirtualAtten...
Starting off with Introductory remarks from Dr François Franceschi of GARDP.
One last round of sessions, discussions and shared learning as the conference draws to a close.
✊Let’s finish strong!
🔴🔗Join us live here: portalapp.bsac.eventsair.com/VirtualAtten...
February 5, 2026 at 8:01 AM
🏁✨Final day of #ACC2026
Starting off with Introductory remarks from Dr François Franceschi of GARDP.
One last round of sessions, discussions and shared learning as the conference draws to a close.
✊Let’s finish strong!
🔴🔗Join us live here: portalapp.bsac.eventsair.com/VirtualAtten...
Starting off with Introductory remarks from Dr François Franceschi of GARDP.
One last round of sessions, discussions and shared learning as the conference draws to a close.
✊Let’s finish strong!
🔴🔗Join us live here: portalapp.bsac.eventsair.com/VirtualAtten...
✨ Day 1 of #ACC2026 wrapped up strong!
From research to real-world practice, today’s sessions delivered strong science, open dialogue and a clear sense of shared purpose across the AMR community.
⏳Missed Day 1? You can still register and join us for Day 2.
🔗 acc-conference.com#registration
From research to real-world practice, today’s sessions delivered strong science, open dialogue and a clear sense of shared purpose across the AMR community.
⏳Missed Day 1? You can still register and join us for Day 2.
🔗 acc-conference.com#registration
February 4, 2026 at 12:16 PM
✨ Day 1 of #ACC2026 wrapped up strong!
From research to real-world practice, today’s sessions delivered strong science, open dialogue and a clear sense of shared purpose across the AMR community.
⏳Missed Day 1? You can still register and join us for Day 2.
🔗 acc-conference.com#registration
From research to real-world practice, today’s sessions delivered strong science, open dialogue and a clear sense of shared purpose across the AMR community.
⏳Missed Day 1? You can still register and join us for Day 2.
🔗 acc-conference.com#registration
🔴#ACC2026 Day 1 I We’re live with today's final session
Equitable TB care is in focus as experts tackle the treatment gaps facing vulnerable populations.
Experts from across Asia are discussing solutions right now.
🔗Join them: portalapp.bsac.eventsair.com/VirtualAtten...
@lshtm.bsky.social
Equitable TB care is in focus as experts tackle the treatment gaps facing vulnerable populations.
Experts from across Asia are discussing solutions right now.
🔗Join them: portalapp.bsac.eventsair.com/VirtualAtten...
@lshtm.bsky.social
February 4, 2026 at 11:02 AM
🔴#ACC2026 Day 1 I We’re live with today's final session
Equitable TB care is in focus as experts tackle the treatment gaps facing vulnerable populations.
Experts from across Asia are discussing solutions right now.
🔗Join them: portalapp.bsac.eventsair.com/VirtualAtten...
@lshtm.bsky.social
Equitable TB care is in focus as experts tackle the treatment gaps facing vulnerable populations.
Experts from across Asia are discussing solutions right now.
🔗Join them: portalapp.bsac.eventsair.com/VirtualAtten...
@lshtm.bsky.social
📣🌏Up next at #ACC2026
A dynamic panel with experts from Singapore, Taiwan and Thailand discussing
- future TB therapies
- TB in pregnancy & childhood
- tackling MDR-TB in LMICs
🔗Be part of the discussion live: portalapp.bsac.eventsair.com/VirtualAtten...
A dynamic panel with experts from Singapore, Taiwan and Thailand discussing
- future TB therapies
- TB in pregnancy & childhood
- tackling MDR-TB in LMICs
🔗Be part of the discussion live: portalapp.bsac.eventsair.com/VirtualAtten...
February 4, 2026 at 10:49 AM
📣🌏Up next at #ACC2026
A dynamic panel with experts from Singapore, Taiwan and Thailand discussing
- future TB therapies
- TB in pregnancy & childhood
- tackling MDR-TB in LMICs
🔗Be part of the discussion live: portalapp.bsac.eventsair.com/VirtualAtten...
A dynamic panel with experts from Singapore, Taiwan and Thailand discussing
- future TB therapies
- TB in pregnancy & childhood
- tackling MDR-TB in LMICs
🔗Be part of the discussion live: portalapp.bsac.eventsair.com/VirtualAtten...
3⃣🚀Session Three has just started at #ACC2026
The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections.
🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten...
The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections.
🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten...
February 4, 2026 at 9:58 AM
3⃣🚀Session Three has just started at #ACC2026
The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections.
🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten...
The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections.
🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten...
👋Attending #ACC2026?
Stop by the GARDP virtual booth where you will find useful resources on our programmes, partnerships and platforms by clicking 'Exhibition' tab on the conference site.
Take a look👇
portalapp.bsac.eventsair.com/VirtualAtten...
Stop by the GARDP virtual booth where you will find useful resources on our programmes, partnerships and platforms by clicking 'Exhibition' tab on the conference site.
Take a look👇
portalapp.bsac.eventsair.com/VirtualAtten...
February 4, 2026 at 9:44 AM
👋Attending #ACC2026?
Stop by the GARDP virtual booth where you will find useful resources on our programmes, partnerships and platforms by clicking 'Exhibition' tab on the conference site.
Take a look👇
portalapp.bsac.eventsair.com/VirtualAtten...
Stop by the GARDP virtual booth where you will find useful resources on our programmes, partnerships and platforms by clicking 'Exhibition' tab on the conference site.
Take a look👇
portalapp.bsac.eventsair.com/VirtualAtten...
🧪✨Now live | Session Two at ACC 2026
From systems views on AMR to novel antibiotics and biofilm control, this session dives into the frontiers of drug discovery.
Tune in now.
portalapp.bsac.eventsair.com/VirtualAtten...
@elisca.bsky.social
@ethz.ch
@mcmasteruniversity.bsky.social
From systems views on AMR to novel antibiotics and biofilm control, this session dives into the frontiers of drug discovery.
Tune in now.
portalapp.bsac.eventsair.com/VirtualAtten...
@elisca.bsky.social
@ethz.ch
@mcmasteruniversity.bsky.social
February 4, 2026 at 8:52 AM
🧪✨Now live | Session Two at ACC 2026
From systems views on AMR to novel antibiotics and biofilm control, this session dives into the frontiers of drug discovery.
Tune in now.
portalapp.bsac.eventsair.com/VirtualAtten...
@elisca.bsky.social
@ethz.ch
@mcmasteruniversity.bsky.social
From systems views on AMR to novel antibiotics and biofilm control, this session dives into the frontiers of drug discovery.
Tune in now.
portalapp.bsac.eventsair.com/VirtualAtten...
@elisca.bsky.social
@ethz.ch
@mcmasteruniversity.bsky.social
📢🪧Check out the #ACC2026 Poster Gallery!
Browse posters, download files and watch author videos clicking the ‘Poster Gallery’ tab at the portal link. Find insights across discovery, clinical work, public health and access.
🔗 portalapp.bsac.eventsair.com/VirtualAtten...
Browse posters, download files and watch author videos clicking the ‘Poster Gallery’ tab at the portal link. Find insights across discovery, clinical work, public health and access.
🔗 portalapp.bsac.eventsair.com/VirtualAtten...
February 4, 2026 at 8:39 AM
📢🪧Check out the #ACC2026 Poster Gallery!
Browse posters, download files and watch author videos clicking the ‘Poster Gallery’ tab at the portal link. Find insights across discovery, clinical work, public health and access.
🔗 portalapp.bsac.eventsair.com/VirtualAtten...
Browse posters, download files and watch author videos clicking the ‘Poster Gallery’ tab at the portal link. Find insights across discovery, clinical work, public health and access.
🔗 portalapp.bsac.eventsair.com/VirtualAtten...
🔴 Keynote now live at #ACC2026
Topic: Optimising multinational clinical trials with antimicrobials and the critical role of clinical trial networks 🧬🌍
Featuring Prof David Paterson, National University of Singapore and ADVANCE-ID.
🔗 bit.ly/4rmSteA
@advance-id.bsky.social
Topic: Optimising multinational clinical trials with antimicrobials and the critical role of clinical trial networks 🧬🌍
Featuring Prof David Paterson, National University of Singapore and ADVANCE-ID.
🔗 bit.ly/4rmSteA
@advance-id.bsky.social
February 4, 2026 at 8:11 AM
🔴 Keynote now live at #ACC2026
Topic: Optimising multinational clinical trials with antimicrobials and the critical role of clinical trial networks 🧬🌍
Featuring Prof David Paterson, National University of Singapore and ADVANCE-ID.
🔗 bit.ly/4rmSteA
@advance-id.bsky.social
Topic: Optimising multinational clinical trials with antimicrobials and the critical role of clinical trial networks 🧬🌍
Featuring Prof David Paterson, National University of Singapore and ADVANCE-ID.
🔗 bit.ly/4rmSteA
@advance-id.bsky.social
🚀 #ACC2026 kicks off today!
This year’s conference is packed with sessions spanning early-stage research, clinical evidence and policy-relevant insights at a critical moment for #AMR.
📌Check the sessions below and register now (if you haven’t already)
🔗 https://eventsair.pulse.ly/7mo5iqqr5v
This year’s conference is packed with sessions spanning early-stage research, clinical evidence and policy-relevant insights at a critical moment for #AMR.
📌Check the sessions below and register now (if you haven’t already)
🔗 https://eventsair.pulse.ly/7mo5iqqr5v
February 4, 2026 at 7:21 AM
🚀 #ACC2026 kicks off today!
This year’s conference is packed with sessions spanning early-stage research, clinical evidence and policy-relevant insights at a critical moment for #AMR.
📌Check the sessions below and register now (if you haven’t already)
🔗 https://eventsair.pulse.ly/7mo5iqqr5v
This year’s conference is packed with sessions spanning early-stage research, clinical evidence and policy-relevant insights at a critical moment for #AMR.
📌Check the sessions below and register now (if you haven’t already)
🔗 https://eventsair.pulse.ly/7mo5iqqr5v
🎗️ This #WorldCancerDay, we’re highlighting why the future of cancer care depends on the future of antibiotics.
Drug-resistant infections already threaten people undergoing cancer treatment. As #AMR rises, progress in cancer care is at risk.
Drug-resistant infections already threaten people undergoing cancer treatment. As #AMR rises, progress in cancer care is at risk.
February 4, 2026 at 5:02 AM
🎗️ This #WorldCancerDay, we’re highlighting why the future of cancer care depends on the future of antibiotics.
Drug-resistant infections already threaten people undergoing cancer treatment. As #AMR rises, progress in cancer care is at risk.
Drug-resistant infections already threaten people undergoing cancer treatment. As #AMR rises, progress in cancer care is at risk.
📣ACC2026 kicks off tomorrow!
Join a global, online and open-access conference our antimicrobial chemotherapy, AMR and the future of antibiotic innovation.
🗓️ 4–5 Feb 2026 | 🌍 Online
🔗 Last chance to register: https://eventsair.pulse.ly/35puv6u0m6
#ACC2026
Join a global, online and open-access conference our antimicrobial chemotherapy, AMR and the future of antibiotic innovation.
🗓️ 4–5 Feb 2026 | 🌍 Online
🔗 Last chance to register: https://eventsair.pulse.ly/35puv6u0m6
#ACC2026
February 3, 2026 at 6:59 AM
📣ACC2026 kicks off tomorrow!
Join a global, online and open-access conference our antimicrobial chemotherapy, AMR and the future of antibiotic innovation.
🗓️ 4–5 Feb 2026 | 🌍 Online
🔗 Last chance to register: https://eventsair.pulse.ly/35puv6u0m6
#ACC2026
Join a global, online and open-access conference our antimicrobial chemotherapy, AMR and the future of antibiotic innovation.
🗓️ 4–5 Feb 2026 | 🌍 Online
🔗 Last chance to register: https://eventsair.pulse.ly/35puv6u0m6
#ACC2026
🤝 GARDP has signed an MoU with Lixa, an emerging biotech based in Western Australia. This MoU establishes a framework to assist LIXA’s preclinical candidate, NeoX-121, a novel unconventional antimicrobial with the potential to become a “resistance breaker”.
January 30, 2026 at 7:53 AM
🤝 GARDP has signed an MoU with Lixa, an emerging biotech based in Western Australia. This MoU establishes a framework to assist LIXA’s preclinical candidate, NeoX-121, a novel unconventional antimicrobial with the potential to become a “resistance breaker”.
⏰One week to go until #ACC2026!
From early antibiotic discovery to real-world clinical use and access, ACC2026 brings together global expertise for 2 days of focused discussion, live Q&A and shared learning.
📅 4–5 Feb 2026 I🌍Free and Online
🔗 Register now: https://eventsair.pulse.ly/lvlg78hsiq
From early antibiotic discovery to real-world clinical use and access, ACC2026 brings together global expertise for 2 days of focused discussion, live Q&A and shared learning.
📅 4–5 Feb 2026 I🌍Free and Online
🔗 Register now: https://eventsair.pulse.ly/lvlg78hsiq
January 28, 2026 at 6:59 AM
⏰One week to go until #ACC2026!
From early antibiotic discovery to real-world clinical use and access, ACC2026 brings together global expertise for 2 days of focused discussion, live Q&A and shared learning.
📅 4–5 Feb 2026 I🌍Free and Online
🔗 Register now: https://eventsair.pulse.ly/lvlg78hsiq
From early antibiotic discovery to real-world clinical use and access, ACC2026 brings together global expertise for 2 days of focused discussion, live Q&A and shared learning.
📅 4–5 Feb 2026 I🌍Free and Online
🔗 Register now: https://eventsair.pulse.ly/lvlg78hsiq
GARDP’s Manica joined MPs from several countries for a luncheon under the Parliamentary Dialogue Programme. Co-hosted by UNITE and the Konrad-Adenauer-Stiftung, it brought together public and private-sector actors, including GSK.
@gsk.bsky.social
@gsk.bsky.social
January 26, 2026 at 12:53 PM
GARDP’s Manica joined MPs from several countries for a luncheon under the Parliamentary Dialogue Programme. Co-hosted by UNITE and the Konrad-Adenauer-Stiftung, it brought together public and private-sector actors, including GSK.
@gsk.bsky.social
@gsk.bsky.social